NCT06379386 Long-term Prognosis and Valve Durability of TAVR
| NCT ID | NCT06379386 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Aortic Valve Stenosis and Insufficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy. 2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form * 1\. Patients with aortic stenosis or aortic valve insufficiency who were evaluated by the Heart team and underwent TAVR therapy * 2\. Patients who understand the purpose of the study, agree to participate in the trial and sign the informed consent form Exclusion Criteria: * 1\. Patients who cannot provide informed consent * 2\. Patients who are participating in other clinical trials
Contact & Investigator
Ling Tao, M.D, Ph.D
STUDY CHAIR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT06379386 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Valve Stenosis and Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06379386 currently recruiting?
Yes, NCT06379386 is actively recruiting participants. Contact the research team at rutaowang@qq.com for enrollment information.
Where is the NCT06379386 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06379386 clinical trial?
NCT06379386 is sponsored by Xijing Hospital. The principal investigator is Ling Tao, M.D, Ph.D at Xijing Hospital. The trial plans to enroll 1,000 participants.